Shamburg News · 8-K filed Nov 3, 2026, 8:30 AM EST
SeaStar Medical Says FDA Confirms QUELIMMUNE SAVE Registry Post-Approval Requirements Fulfilled
ICU · SeaStar Medical Holding Corp
- Other event
- Materiality: medium
On November 3, 2026, SeaStar Medical Holding Corporation announced that the FDA's CBER determined the QUELIMMUNE Pediatric SAVE Surveillance Registry has fulfilled the post-approval study requirements of the original Humanitarian Device Exemption approval. The company reported ASN Kidney Week 2026 registry data showing 90-day survival of 65.1% (N=43) versus 47.5% (N=196) for KID cohorts, and said the decision allows hospitals to use the therapy without the registry's research infrastructure.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001437749-26-034531.
Written from the filing by Shamburg Markets. Figures are as reported by the company.